|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EMC7 |
Gene summary for EMC7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EMC7 | Gene ID | 56851 |
| Gene name | ER membrane protein complex subunit 7 | |
| Gene Alias | C11orf3 | |
| Cytomap | 15q14 | |
| Gene Type | protein-coding | GO ID | GO:0006996 | UniProtAcc | Q9NPA0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 56851 | EMC7 | HTA11_2487_2000001011 | Human | Colorectum | SER | 8.37e-03 | 2.95e-01 | -0.1808 |
| 56851 | EMC7 | HTA11_347_2000001011 | Human | Colorectum | AD | 1.82e-07 | 3.46e-01 | -0.1954 |
| 56851 | EMC7 | HTA11_1391_2000001011 | Human | Colorectum | AD | 1.06e-02 | 3.39e-01 | -0.059 |
| 56851 | EMC7 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 2.71e-03 | 3.19e-01 | 0.294 |
| 56851 | EMC7 | A002-C-016 | Human | Colorectum | FAP | 3.61e-02 | -6.71e-02 | 0.0521 |
| 56851 | EMC7 | A002-C-116 | Human | Colorectum | FAP | 8.13e-03 | -8.85e-02 | -0.0452 |
| 56851 | EMC7 | LZE4T | Human | Esophagus | ESCC | 9.88e-19 | 5.12e-01 | 0.0811 |
| 56851 | EMC7 | LZE5T | Human | Esophagus | ESCC | 3.10e-03 | 5.39e-01 | 0.0514 |
| 56851 | EMC7 | LZE7T | Human | Esophagus | ESCC | 1.00e-02 | 4.53e-01 | 0.0667 |
| 56851 | EMC7 | LZE8T | Human | Esophagus | ESCC | 2.23e-04 | 2.39e-01 | 0.067 |
| 56851 | EMC7 | LZE22T | Human | Esophagus | ESCC | 4.38e-04 | 3.71e-01 | 0.068 |
| 56851 | EMC7 | LZE24T | Human | Esophagus | ESCC | 1.05e-18 | 6.48e-01 | 0.0596 |
| 56851 | EMC7 | LZE6T | Human | Esophagus | ESCC | 1.58e-08 | 2.19e-01 | 0.0845 |
| 56851 | EMC7 | P1T-E | Human | Esophagus | ESCC | 2.47e-06 | 6.63e-01 | 0.0875 |
| 56851 | EMC7 | P2T-E | Human | Esophagus | ESCC | 9.22e-28 | 3.69e-01 | 0.1177 |
| 56851 | EMC7 | P4T-E | Human | Esophagus | ESCC | 9.40e-42 | 1.12e+00 | 0.1323 |
| 56851 | EMC7 | P5T-E | Human | Esophagus | ESCC | 1.30e-28 | 8.08e-01 | 0.1327 |
| 56851 | EMC7 | P8T-E | Human | Esophagus | ESCC | 7.32e-43 | 9.34e-01 | 0.0889 |
| 56851 | EMC7 | P9T-E | Human | Esophagus | ESCC | 1.46e-32 | 8.11e-01 | 0.1131 |
| 56851 | EMC7 | P10T-E | Human | Esophagus | ESCC | 6.87e-43 | 9.12e-01 | 0.116 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0090150 | Colorectum | AD | establishment of protein localization to membrane | 100/3918 | 260/18723 | 6.01e-11 | 6.33e-09 | 100 |
| GO:0051205 | Colorectum | AD | protein insertion into membrane | 23/3918 | 57/18723 | 6.62e-04 | 6.80e-03 | 23 |
| GO:0007029 | Colorectum | AD | endoplasmic reticulum organization | 31/3918 | 87/18723 | 1.08e-03 | 1.00e-02 | 31 |
| GO:00901501 | Colorectum | SER | establishment of protein localization to membrane | 68/2897 | 260/18723 | 5.55e-06 | 2.01e-04 | 68 |
| GO:00512051 | Colorectum | SER | protein insertion into membrane | 19/2897 | 57/18723 | 6.32e-04 | 8.58e-03 | 19 |
| GO:00070291 | Colorectum | SER | endoplasmic reticulum organization | 23/2897 | 87/18723 | 5.77e-03 | 4.23e-02 | 23 |
| GO:00901502 | Colorectum | MSS | establishment of protein localization to membrane | 90/3467 | 260/18723 | 4.11e-10 | 3.49e-08 | 90 |
| GO:00512052 | Colorectum | MSS | protein insertion into membrane | 21/3467 | 57/18723 | 8.53e-04 | 8.75e-03 | 21 |
| GO:00901504 | Colorectum | FAP | establishment of protein localization to membrane | 69/2622 | 260/18723 | 6.40e-08 | 4.54e-06 | 69 |
| GO:0090150110 | Esophagus | ESCC | establishment of protein localization to membrane | 182/8552 | 260/18723 | 1.27e-15 | 8.19e-14 | 182 |
| GO:000702914 | Esophagus | ESCC | endoplasmic reticulum organization | 65/8552 | 87/18723 | 3.28e-08 | 6.08e-07 | 65 |
| GO:005120515 | Esophagus | ESCC | protein insertion into membrane | 46/8552 | 57/18723 | 5.90e-08 | 1.04e-06 | 46 |
| GO:004504812 | Esophagus | ESCC | protein insertion into ER membrane | 21/8552 | 22/18723 | 8.75e-07 | 1.13e-05 | 21 |
| GO:007181611 | Esophagus | ESCC | tail-anchored membrane protein insertion into ER membrane | 17/8552 | 17/18723 | 1.63e-06 | 1.95e-05 | 17 |
| GO:00450503 | Esophagus | ESCC | protein insertion into ER membrane by stop-transfer membrane-anchor sequence | 10/8552 | 10/18723 | 3.94e-04 | 2.26e-03 | 10 |
| GO:00901507 | Liver | Cirrhotic | establishment of protein localization to membrane | 123/4634 | 260/18723 | 1.85e-15 | 2.15e-13 | 123 |
| GO:00070292 | Liver | Cirrhotic | endoplasmic reticulum organization | 42/4634 | 87/18723 | 1.67e-06 | 3.22e-05 | 42 |
| GO:00512053 | Liver | Cirrhotic | protein insertion into membrane | 29/4634 | 57/18723 | 1.88e-05 | 2.53e-04 | 29 |
| GO:0045048 | Liver | Cirrhotic | protein insertion into ER membrane | 11/4634 | 22/18723 | 9.18e-03 | 4.21e-02 | 11 |
| GO:009015012 | Liver | HCC | establishment of protein localization to membrane | 168/7958 | 260/18723 | 4.07e-13 | 2.13e-11 | 168 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EMC7 | SNV | Missense_Mutation | novel | c.184A>G | p.Ile62Val | p.I62V | Q9NPA0 | protein_coding | tolerated(0.73) | benign(0.003) | TCGA-E2-A56Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
| EMC7 | SNV | Missense_Mutation | c.420N>T | p.Met140Ile | p.M140I | Q9NPA0 | protein_coding | tolerated(0.33) | benign(0.006) | TCGA-A6-6141-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | 5-fu | SD | |
| EMC7 | SNV | Missense_Mutation | novel | c.696N>C | p.Lys232Asn | p.K232N | Q9NPA0 | protein_coding | tolerated(0.08) | benign(0.264) | TCGA-AA-3973-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Targeted Molecular therapy | bevacizumab | SD |
| EMC7 | SNV | Missense_Mutation | novel | c.696N>C | p.Lys232Asn | p.K232N | Q9NPA0 | protein_coding | tolerated(0.08) | benign(0.264) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| EMC7 | SNV | Missense_Mutation | c.341C>T | p.Ser114Leu | p.S114L | Q9NPA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.715) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| EMC7 | SNV | Missense_Mutation | c.341N>T | p.Ser114Leu | p.S114L | Q9NPA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.715) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| EMC7 | SNV | Missense_Mutation | c.464N>T | p.Trp155Leu | p.W155L | Q9NPA0 | protein_coding | deleterious(0.01) | probably_damaging(0.913) | TCGA-AZ-6601-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| EMC7 | SNV | Missense_Mutation | novel | c.226N>A | p.Gly76Ser | p.G76S | Q9NPA0 | protein_coding | deleterious(0.01) | probably_damaging(0.925) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
| EMC7 | SNV | Missense_Mutation | c.341N>T | p.Ser114Leu | p.S114L | Q9NPA0 | protein_coding | deleterious(0.01) | possibly_damaging(0.715) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| EMC7 | SNV | Missense_Mutation | c.595A>C | p.Asn199His | p.N199H | Q9NPA0 | protein_coding | deleterious(0) | possibly_damaging(0.483) | TCGA-A5-A0GP-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |